FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lang Daniel
2. Date of Event Requiring Statement (MM/DD/YYYY)
11/22/2021 

3. Issuer Name and Ticker or Trading Symbol

Athenex, Inc. [ATNX]
(Last)        (First)        (Middle)

C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Pres Cell Therapy, VP Corp Dev /
(Street)

BUFFALO, NY 14203      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 73413 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)  (2)8/27/2030 Common Stock 40000 $10.25 D  
Stock Option (Right to Buy)  (3)9/16/2031 Common Stock 50000 $2.77 D  
Restricted Stock Units  (4) (4)Common Stock 50000  (5)D  

Explanation of Responses:
(1) Includes 30,000 shares subject to a restricted stock award vesting in four equal installments beginning on August 26, 2020.
(2) This option vests in four equal annual installments beginning on August 27, 2021.
(3) This option vests in four equal annual installments beginning on September 16, 2022.
(4) The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
(5) Each restricted stock unit represents a contingent right to receive one share of stock.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Lang Daniel
C/O ATHENEX, INC., 1001 MAIN STREET
SUITE 600
BUFFALO, NY 14203


Pres Cell Therapy, VP Corp Dev

Signatures
/s/Steven Adams, Attorney-in-Fact12/1/2021
**Signature of Reporting PersonDate

Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Athenex Charts.
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Athenex Charts.